SCHEDULE: Schonfeld Strategic Advisors Reports 5.48% Stake in Mersana
Beneficial Ownership Report
Schonfeld Strategic Advisors LLC has reported a 5.48% beneficial ownership stake in Mersana Therapeutics, Inc., holding 273,579 shares of common stock.
Summary
- Schonfeld Strategic Advisors LLC, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of Mersana Therapeutics, Inc. common stock.
- The reporting person beneficially owns 273,579 shares of Mersana Therapeutics, Inc. common stock.
- This ownership represents 5.48% of the issuer's common stock outstanding.
- The percentage is calculated based on 4,990,692 shares of common stock outstanding as of August 8, 2025.
- Schonfeld Strategic Advisors LLC holds sole voting power and sole dispositive power over all 273,579 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting a beneficial ownership stake. It provides no operational or financial performance data to assess sentiment.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Mersana Therapeutics, Inc.'s future performance or operations.
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment adviser, indicating a passive investment stake in Mersana Therapeutics, Inc. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of an institutional investor's position in the company.
Stakeholder Impact
- Shareholders: The filing indicates a significant institutional investor, Schonfeld Strategic Advisors LLC, holds a 5.48% stake, which could be viewed as a vote of confidence or simply a portfolio allocation decision. It does not suggest any intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-08-08 | Date as of which 4,990,692 shares of common stock were outstanding, used for percentage calculation. |
| 2025-08-13 | Date of issuer's definitive proxy statement filing with the SEC. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-11-14 | Date the Schedule 13G statement was signed by Schonfeld Strategic Advisors LLC. |
Keywords
Mersana Therapeutics, Schonfeld Strategic Advisors, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, MRSN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.